This Wiley B-Cell Malignancies Knowledge Hub publishes the latest clinically relevant content from trusted sources on the therapeutic advances in B-cell malignancies with a special focus on Bruton’s tyrosine kinase inhibitors (BTKi) so that HCPs provide individualized treatment strategies that optimize outcomes for patients with B-cell malignancies.
The aim of the Knowledge Hub is to educate relevant healthcare professionals on the latest research, and provide them with the tools to easily apply the latest recommendations to make meaningful interventions in best-patient care.
All content published on the resource is reviewed by our independent expert editorial panel and presented in an accessible format for easy application in everyday clinical practice.
The resource has been supported by Eli Lilly. The supporter has had no influence in the selection of the Editorial Panel or the creation of content.
Stay Up To Date
Join the Wiley Knowledge Hub mailing list to stay up to date with the latest research and education in your area of interest.